Healthtech startup CureMeAbroad has raised $1.1 million in a pre-seed funding spherical led by healthcare-focused enterprise capital fund SteerX Ventures, with current investor AIRA additionally taking part.

The startup mentioned the contemporary capital might be used to broaden its community of accredited hospitals, enter new affected person supply markets and strengthen its AI-powered expertise. It additionally plans to construct its operations and expertise groups.

CureMeAbroad can also be seeking to broaden its therapy choices into non-elective specialties, together with orthopaedics and oncology, and is exploring bodily expertise centres in key worldwide markets.

The most recent funding follows a $600,000 pre-seed spherical introduced in April 2026, which included backing from Roman Saini, Himanshu Ratnoo, Kunal Gupta, Devaiah Bopanna, Vikrant Potnis and AIRA Buildon.

What does CureMeAbroad do?

Based in June 2025 by Aditya Oza and Mikhail Bohra, Pune-headquartered CureMeAbroad helps sufferers in search of therapy abroad discover and examine hospitals and organize their care.

Its platform permits sufferers to test healthcare suppliers in opposition to Joint Fee Worldwide, or JCI, accreditation or equal nationwide requirements, get hold of therapy estimates and guide care. It additionally gives help through the therapy journey.

CureMeAbroad’s platform combines healthcare discovery, therapy planning, pricing transparency and affected person help.

CureMeAbroad at the moment attracts greater than 22,500 guests a month and operates a hospital community spanning six international locations. In September, World Healthcare Accreditation, or GHA, awarded CureMeAbroad its Medical Journey Facilitator Certification.

GHA mentioned the corporate’s community contains greater than 400 accredited hospital companions throughout six international locations and helps sufferers from their preliminary search and comparability of therapy choices via to therapy and post-treatment follow-up.

The accreditation physique additionally mentioned CureMeAbroad primarily serves sufferers from Western markets, together with the US, UK, Australia and Canada.

Plans to broaden the platform

CureMeAbroad mentioned the brand new funding will permit it to enter further affected person supply markets whereas increasing its current hospital community.

“SteerX did not want convincing that this class wants an AI-native platform,” Oza mentioned.

The startup has additionally recognized orthopaedics and oncology as areas for enlargement because it strikes additional into non-elective remedies.

Lalit Singla, founder and CEO of SteerX Ventures, mentioned price pressures and delays in some healthcare techniques have been contributing to curiosity in therapy overseas.

“Excessive healthcare prices and lengthy ready intervals are encouraging sufferers in markets such because the US, Europe and Australia to discover high quality care throughout borders,” Singla mentioned.

He added that CureMeAbroad was growing expertise and infrastructure geared toward making the cross-border healthcare course of extra trusted and seamless.

Concentrating on $100 million in annual therapy bookings

CureMeAbroad is focusing on $100 million in annual affected person therapy bookings by FY2028, in contrast with what it mentioned is a present run charge of $4.8 million.

Its key affected person supply markets at the moment embrace the US, UK, Australia and Canada.

The funding comes as CureMeAbroad seeks to construct a broader platform across the totally different phases concerned in arranging therapy abroad, from discovering and evaluating healthcare suppliers to estimating prices, reserving therapy and receiving help through the course of.

SteerX Ventures focuses on early-stage healthcare corporations, investing from pre-seed via Sequence A. Its funding areas embrace healthcare supply, diagnostics and therapy, digital well being and AI, medical units, biotechnology and healthcare fintech.